Glucocorticoid Receptor Antagonist Approved for Ovarian Cancer

Relacorilant, a first-in-class glucocorticoid receptor antagonist, earned approval on March 25 for platinum-resistant ovarian cancer, after phase III data showed it improved progression-free and overall survival when added to chemotherapy. Because its use does not depend on tumor biomarker status, the therapy could reach a broader patient population than recently approved alternatives.